TRAIL1 (ClinicalTrials.gov Identifier: NCT02808871) was a phase 2 randomised, double blind, placebo-controlled trial investigating pirfenidone in rheumatoid arthritis-associated interstitial lung disease (RA-ILD). We were delighted to speak to Professor Ivan O. Rosas (Baylor College of Medicine, Baylor Medicine McNair Campus, Houston, TX, USA) around the aims, design and inclusion criteria of the TRAIL1 study and the safety, tolerability and efficacy findings and what these mean for the treatment paradigm for RA-ILD.
The abstract ‘Randomized, Double Blinded, Placebo-Controlled, Phase 2 Study of Safety, Tolerability and Efficacy of Pirfenidone in Patients with Rheumatoid Arthritis Interstitial Lung Disease.‘ (Abstract number: RCT2886) was presented at ERS 2022, 4–6 September, 2022.
- What is the rationale for the use of pirfenidone in the treatment of RA-ILD? (0:52)
- What were the aims, design and inclusion criteria of the TRAIL1 study? (3:33)
- What were the primary and secondary endpoints of the study and how well were they achieved? (5:08)
- What is the clinical significance of these findings? (7:50)
Disclosures: Ivan O. Rosas discloses consulting for Genentech/Roche and receiving grant/ research support from Genentech/Roche.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the ERS meeting 2022.
Share this Video
Related Videos In Interstitial Lung Disease
Jean Elwing, CHEST 2022: Inhaled treprostinil for pulmonary hypertension due to interstitial lung disease – the INCREASE OLE study
INCREASE OLE was the open-label extension of the INCREASE study (NCT02630316), which investigated the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease. We caught up with Prof. Jean Elwing (UC Health, Cincinnati, OH, USA) to discuss the methodology, inclusion criteria, and safety and tolerability findings from the […]
Junelle Speller – The Pulmonary Fibrosis Foundation Community Registry
The Pulmonary Fibrosis Foundation (PFF) Registry is collecting data from patients with pulmonary fibrosis (PF) or interstitial lung disease (ILD), lung transplant recipients who have had PF or ILD as well as caregivers and family members of patients to help advance medical research. It was a pleasure to talk with PFF Vice President, Junelle Speller […]
Junelle Speller: Pulmonary Fibrosis Foundation – Unmet Needs in Pulmonary Fibrosis and Interstitial Lung Disease
The Pulmonary Fibrosis Foundation (PFF) Registry is collecting data from patients with pulmonary fibrosis (PF) or interstitial lung disease (ILD), lung transplant recipients who have had PF or ILD as well as caregivers and family members of patients to help advance medical research. touchRESPIRATORY were delighted to talk to PFF Vice President, Junelle Speller around […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!